ASCO
I did not locate any ISIS presentations coming up at ASCO in June 2012, but please let me know if I missed one. Note that partner Oncogenex $OGXI will be presenting and I will cover their data separately on the blog.
1q-2012 pharma partner updates
Keep reading below for information from Biogen $BIIB, Bristol Myers Squibb $BMY, Eli Lilly $LLY, and Sanofi $SNY
I did not locate any ISIS presentations coming up at ASCO in June 2012, but please let me know if I missed one. Note that partner Oncogenex $OGXI will be presenting and I will cover their data separately on the blog.
1q-2012 pharma partner updates
Keep reading below for information from Biogen $BIIB, Bristol Myers Squibb $BMY, Eli Lilly $LLY, and Sanofi $SNY
--Biogen 1q-2012 conference call:
"This quarter, we also began dosing patients in the Phase I program for ISIS-SMN for the treatment of Spinal Muscular Atrophy and expect to see results late in 2013.”
--Bristol Myers Squibb - note that the PCKS9 program with ISIS was announced as abandoned earlier this year, so there was no discussion.
--Sanofi 1q-2012 conference call:
"This [KYNAMRO] is an important population for us because, although a little bit more severe, this really relates the groundwork for the PCSK9 coming along which even though will have a higher – will have a larger patient population it gets us already involved in this field commercially."
--Eli Lilly 1q-2012 conference call:
"In addition, we terminated development of four molecules; three in Phase II and one in Phase I."
Note that one of the phase 2 casualties was the antisense survivin inhibitor for cancer licensed from ISIS. See the updated LLY pipeline here for the proof. Isis Pharma finally disclosed this news weeks later on their 1q-2012 conference call.
"This quarter, we also began dosing patients in the Phase I program for ISIS-SMN for the treatment of Spinal Muscular Atrophy and expect to see results late in 2013.”
--Bristol Myers Squibb - note that the PCKS9 program with ISIS was announced as abandoned earlier this year, so there was no discussion.
--Sanofi 1q-2012 conference call:
"This [KYNAMRO] is an important population for us because, although a little bit more severe, this really relates the groundwork for the PCSK9 coming along which even though will have a higher – will have a larger patient population it gets us already involved in this field commercially."
--Eli Lilly 1q-2012 conference call:
"In addition, we terminated development of four molecules; three in Phase II and one in Phase I."
Note that one of the phase 2 casualties was the antisense survivin inhibitor for cancer licensed from ISIS. See the updated LLY pipeline here for the proof. Isis Pharma finally disclosed this news weeks later on their 1q-2012 conference call.
RSS Feed
